Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thymus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43 result(s) found for: Thymus. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2010-019683-37 Sponsor Protocol Number: ONC-2010-001 Start Date*: 2011-01-21
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: PHASE II STUDY OF EVEROLIMUS IN PATIENTS WITH THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY
    Medical condition: Chemotherapy pre-treated thymoma and thymic carcinoma patients who have had at least one prior platinum-containing chemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056296 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002561-21 Sponsor Protocol Number: IFCT-1604 Start Date*: 2018-02-02
    Sponsor Name:IFCT
    Full Title: Randomised Open Label Adaptive Phase III trial of addition of Belinostat to chemotherapy in patients with locally advanced potentially resectable Thymic Epithelial Tumors (TET)
    Medical condition: Locally advanced potentially resectable Thymic Epithelial Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061031 Thymoma malignant PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026533 Malignant neoplasm of thymus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004494-13 Sponsor Protocol Number: INT-TET1-7371 Start Date*: 2018-04-09
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: IMPROVING TREATMENT STRATEGIES IN THYMIC EPITHELIAL TUMORS: A TYME COLLABORATIVE EFFORT
    Medical condition: Patients diagnosed with thymic carcinoma / thymoma B3 with areas of carcinoma with metastatic or relapsed non-pre-treated disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056296 Neoplasm of thymus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002872-17 Sponsor Protocol Number: CSOM230DIC03 Start Date*: 2013-06-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and th...
    Medical condition: Neouroendocrine carcinoma of the lung and thymus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025064 Lung carcinoma LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) FR (Prematurely Ended) NL (Prematurely Ended) DK (Completed) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005504-28 Sponsor Protocol Number: EORTC-1525-LCG Start Date*: 2017-12-19
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)
    Medical condition: type B3 thymoma and thymic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061031 Thymoma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) ES (Temporarily Halted) NL (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-012260-14 Sponsor Protocol Number: 20050418 Start Date*: 2010-08-27
    Sponsor Name:Department of Endocrine Oncology
    Full Title: An open, non-randomized phase-2 study of efficacy and safety of treatment with 177Lutetium-DOTA0-Tyr3-octreotate in patients with neuroendocrine tumors
    Medical condition: Patients with malignant neuroendocrine tumours, not amenable to surgical treatment or radiofrequency ablation. Renal, bone marrow and liver function must be sufficient.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001468-12 Sponsor Protocol Number: PEN-221-001 Start Date*: 2017-01-16
    Sponsor Name:Tarveda Therapeutics, Inc.
    Full Title: A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing ad...
    Medical condition: Somatostatin receptor 2 (SSTR2) expressing advanced cancers, including gastroenteropancreatic (GEP) cancer or lung cancer or thymus cancer or other NETs (Neuroendocrine tumour) or small cell lung c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002522-36 Sponsor Protocol Number: CPDR001E2201 Start Date*: 2016-12-29
    Sponsor Name:Novartis Pharma AG
    Full Title: An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin...
    Medical condition: Advanced neuroendocrine tumor (NET) of pancreatic, GI lung origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), that have progressed on prior treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001413-34 Sponsor Protocol Number: VIHCREC01 Start Date*: 2005-04-21
    Sponsor Name:Bonaventura Clotet Sala
    Full Title: ESTUDIO DE UNA DOBLE ESTRATEGIA PARA INDUCIR Y EXPANDIR EL REPERTORIO DE CÉLULAS T BASADA EN LA ADMINISTRACIÓN DE HORMONA DE CRECIMIENTO Y VACUNA EN PACIENTES CON INFECCIÓN POR EL VIH 1
    Medical condition: HIV-1
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023827-34 Sponsor Protocol Number: 1585/10 Start Date*: 2011-05-02
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PHASE III CLINICAL TRIAL TO ASSESS THE ADDED ROLE OF 68Ga-DOTANOC PET-CT IN PATIENTS WITH NEUROENDOCRINE TUMORS
    Medical condition: neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052399 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002647-27 Sponsor Protocol Number: 092004 Start Date*: 2005-03-10
    Sponsor Name:Universitätsklinik für Kinder-und Jugendheilkunde
    Full Title: FSME (human tick-borne encephalitis) - vaccination in children after thymectomy
    Medical condition: In children who undergo open heart surgery because of heart vitium, for surgical reasons the thymus has to be removed. If thymectomy in early childhood alters the function of the immunsystem has be...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005579-10 Sponsor Protocol Number: A-93-52030-325 Start Date*: 2016-02-26
    Sponsor Name:IPSEN S.P.A.
    Full Title: EFFICACY AND SAFETY OF LANREOTIDE ATG 120 MG IN COMBINATION WITH TEMOZOLOMIDE IN SUBJECTS WITH PROGRESSIVE WELL DIFFERENTIATED THORACIC NEUROENDOCRINE TUMORS
    Medical condition: progressive well differentiated thoracic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007282 Carcinoid tumour pulmonary PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037342 Pulmonary carcinoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068115 Metastatic carcinoid tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068118 Metastatic carcinoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019017-25 Sponsor Protocol Number: CSOM230CIC01T Start Date*: Information not available in EudraCT
    Sponsor Name:Freistaat Bayern, represented by Universität Regensburg
    Full Title: Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size
    Medical condition: Primary inoperable thymoma and/or local recurrent thymoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043670 Thymoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005606-30 Sponsor Protocol Number: CAM-THY Start Date*: 2012-04-25
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY
    Medical condition: This trial will test the efficacy of Kepivance in the prevention of new autoimmune diseases in patients who have multiple sclerosis (MS)who are being treated with alemtuzumab.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10058948 Nephritis autoimmune PT
    14.1 10014698 - Endocrine disorders 10049046 Autoimmune thyroiditis PT
    14.1 10021428 - Immune system disorders 10061664 Autoimmune disorder PT
    14.1 10014698 - Endocrine disorders 10068004 Autoimmune hyperthyroidism LLT
    14.1 10005329 - Blood and lymphatic system disorders 10050245 Autoimmune thrombocytopenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000397-18 Sponsor Protocol Number: MedOPP341 Start Date*: 2021-07-15
    Sponsor Name:Medica Scientia Innovation Research S.L (MEDSIR)
    Full Title: A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma PaTIents. PECATI.
    Medical condition: Metastatic Thymic Carcinoma & B3-thymoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043670 Thymoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002530-14 Sponsor Protocol Number: SI101-02 Start Date*: 2023-03-10
    Sponsor Name:SMART IMMUNE
    Full Title: An open-label, multi-center phase I/II study to assess the safety and the efficacy of SMART101 after -haploidentical peripheral blood stem transplantation with post-transplant cyclophosphamide in s...
    Medical condition: Patients with hematological malignancies requiring haploidentical peripheral blood stem transplantation with post-transplant cyclophosphamide
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005762-34 Sponsor Protocol Number: MGCDB001 Start Date*: 2021-07-15
    Sponsor Name:Medical University of Lublin
    Full Title: A phase 2 clinical trial assessing the efficacy and safety of adding cladribine for treatment modifying course of seropositive myasthenia gravis
    Medical condition: Myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002856-28 Sponsor Protocol Number: UF94602 Start Date*: 2015-07-20
    Sponsor Name:CHU de Montpellier
    Full Title: Utilisation de l’Ultiva® associé à la Xylocaïne® dans les procédures de fœticide : essai randomisé de phase III
    Medical condition: Interruptions Médicales de Grossesse (IMG)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10043406 Therapeutic abortion LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004048-38 Sponsor Protocol Number: IEO689 Start Date*: 2019-02-20
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A phase II study of Avelumab in combination with Axitinib in patients with advanced Thymic epithelial tumours (TET)
    Medical condition: Histologically confirmed advanced Thymoma B3 or Thymic carcinoma inoperable (Masaoka Stage IIIb or IV).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003199-27 Sponsor Protocol Number: STYLE Start Date*: 2016-11-17
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: PHASE II TRIAL OF SUNITINIB IN PATIENTS WITH TYPE B3 THYMOMA OR THYMIC CARCINOMA IN SECOND AND FURTHER LINES
    Medical condition: B3 thimoma or thymic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043670 Thymoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 08:41:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA